As such, the integration of molecular signature analyses of mTOR-Hippo signaling may hold potential for the development of a prognostic prediction model for HCC, offering clinicians a powerful tool for assessing patient outcomes and guiding personalized therapeutic strategies. This evidence concerns the gene MTOR and hepatocellular carcinoma.